[en] PURPOSE OF REVIEW: The burden of fractures is very high in patients with chronic kidney disease (CKD). It is increasingly recognized that knowledge of bone turnover is of paramount importance in guiding mineral metabolism and osteoporosis therapy in CKD. Bone histomorphometry is the gold standard to assess bone turnover, but is seldomly performed in clinical practice. Bone turnover markers (BTMs) may be the long awaited noninvasive diagnostic that may help to close the therapeutic gap in patients with advanced CKD presenting with bone fragility.
RECENT FINDINGS: Mounting evidence indicates that BTMs may be useful in skeletal and nonskeletal risk stratification, in guiding mineral metabolism and osteoporosis therapy, and in monitoring the therapeutic response.
SUMMARY: BTMs provide information that is complementary to other clinical tests. It may be envisioned that in the near future, the assessment of nonkidney cleared BTMs may become part of routine clinical evaluation and monitoring of bone health in CKD patients, integrated with clinical risk factors, imaging data and, eventually, bone histomorphometry. Panels of BTMs will likely be more informative than single markers, and the same might hold true for trends as opposed to single time point data.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Smout, Dieter; Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven ; Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
Jørgensen, Hanne S; Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven ; Department of Kidney Diseases, Aarhus University Hospital, Aarhus, Denmark
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique
Evenepoel, Pieter; Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven ; Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
Language :
English
Title :
Clinical utility of bone turnover markers in patients with chronic kidney disease.
Publication date :
01 July 2022
Journal title :
Current Opinion in Nephrology and Hypertension
ISSN :
1062-4821
eISSN :
1473-6543
Publisher :
Ovid Technologies (Wolters Kluwer Health), England
Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. kidney int 2006; 70:1358-1366.
Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288:3014-3018.
Jorgensen HS, David K, Salam S, Evenepoel P. Traditional and nontraditional risk factors for osteoporosis in CKD. Calcif Tissue Int 2021; 108:496-511.
Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 2014; 85:166-173.
Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int 2014; 86:810-818.
Evenepoel P, Cunningham J, Ferrari S, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant 2020; 36:42-59.
Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol 2018; 13:962-969.
Torres PU, Bover J, Mazzaferro S, et al. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol 2014; 34:612-625.
Evenepoel P, D'Haese P, Bacchetta J, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant 2017; 32:1608-1613.
Park PSU, Raynor WY, Sun Y, et al. (18)F-sodium fluoride PET as a diagnostic modality for metabolic, autoimmune, and osteogenic bone disorders: cellular mechanisms and clinical applications. Int J Mol Sci 2021; 22:6504.
Inoue K, Ng C, Xia Y, Zhao B. Regulation of osteoclastogenesis and bone resorption by miRNAs. Front Cell Dev Biol 2021; 9:651161.
Liu J, Dang L, Wu X, et al. microRNA-mediated regulation of bone remodeling: a brief review. JBMR Plus 2019; 3:e10213.
Nickolas TL, Chen N, McMahon DJ, et al. A microRNA approach to discriminate cortical low bone turnover in renal osteodystrophy. JBMR Plus 2020; 4:e10353.
Jeong S, Oh JM, Oh KH, Kim IW. Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients. PLoS One 2017; 12:e0170535.
Amling M, Herden S, Posl M, et al. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res 1996; 11:36-45.
Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012; 8:379-389.
Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013; 61:847-848.
Sardiwal S, Gardham C, Coleman AE, et al. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012; 82:100-105.
Cavalier E, Lukas P, Bottani M, et al. European Biological Variation Study (EuBIVAS): within-and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLMWorking Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporos Int 2020; 31:1461-1470.
Vasikaran SD, Miura M, Pikner R, et al. Practical considerations for the clinical application of bone turnover markers in osteoporosis. Calcif Tissue Int 2021; doi: 10.1007/s00223-021-00930-4. [Online ahead of print]
Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int 1999; 10:399-407.
Ivaska KK, Gerdhem P, Akesson K, et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007; 22:1155-1164.
Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26:1368-1376.
Chavassieux P, Portero-Muzy N, Roux JP, et al. Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 2015; 100:4662-4668.
Evenepoel P, Cavalier E, D'Haese PC. Biomarkers predicting bone turnover in the setting of CKD. Curr Osteoporos Rep 2017; 15:178-186.
Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 2017; 5:908-923.
Crandall CJ, Vasan S, LaCroix A, et al. Bone turnover markers are not associated with hip fracture risk: a case-control study in the women's health initiative. J Bone Miner Res 2018; 33:1199-1208.
Maruyama Y, Taniguchi M, Kazama JJ, et al. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant 2014; 29:1532-1538.
Fishbane S, Hazzan AD, Jhaveri KD, et al. Bone parameters and risk of hip and femur fractures in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11:1063-1072.
Haarhaus M, Evenepoel P. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. kidney int 2021; 100:546-558.
Ott SM, Malluche HH, Jorgetti V, Elder GJ. Importance of bone turnover for therapeuticdecisions in patientswithCKD-MBD.Kidney Int2021;100:502-505.
Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11:337-349.
Evenepoel P, Claes K, Meijers B, et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. kidney int 2019; 95:1461-1470.
Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 2014; 9:1254-1262.
Evenepoel P, Claes K, Meijers B, et al. Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant 2020; 35:697-705.
Viaene L, Evenepoel P, Bammens B, et al. Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract 2008; 110:c80-c85.
Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132:27-39.
Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant 2021; 36:1900-1907.
Hiramatsu R, Ubara Y, Sawa N, et al. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial. Am J Kidney Dis 2015; 66:175-177.
Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74:655-663.
Taliercio JJ, Schold JD, Simon JF, et al. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis 2013; 62:703-710.
Chen J, Mohler ER, Xie D, et al. Traditional and nontraditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31:1145-1151.
Sumida K, Molnar MZ, Potukuchi PK, et al. Prognostic significance of preendstage renal disease serum alkaline phosphatase for postend-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis. Nephrol Dial Transplant 2018; 33:264-273.
Kobayashi I, Shidara K, Okuno S, et al. Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. Life Sci 2012; 90:212-218.
Jorgensen HS, Behets G, Viaene L, et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 2021; S0272-6386(21)00946-X. doi: 10.1053/j.ajkd.2021.07.027. [Online ahead of print]
Salam S, Gallagher O, Gossiel F, et al. Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 2018; 29:1557-1565.
Urena P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7:506-512.
Evenepoel P, Bover J, Urena TP. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 2016; 90:1184-1190.
Seeman E, Nguyen TV. Bone remodeling markers: so easy to measure, so difficult to interpret. Osteoporos Int 2016; 27:33-35.
Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2016; 27:21-31.
Bauer DC, Black DM, Bouxsein ML, et al. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression. J Bone Miner Res 2018; 33:634-642.
Cavalier E, Vasikaran S, Bhattoa HP, et al. The path to the standardization of PTH: is this a realistic possibility? a position paper of the IFCC C-BM. Clin Chim Acta 2021; 515:44-51.
Cavalier E, Lukas P, Delanaye P. Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations. Clin Chem Lab Med 2021; 60:394-400.
Bhattoa HP, Cavalier E, Eastell R, et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and beta-CTX in blood. Clin Chim Acta 2021; 515:16-20.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
